At a glance
ClinicalIndex Comparison RecordN/ACompleted· 83 enrolled
Drug / intervention
Tofacitinib +1 moredrug
Likely dose
Tofacitinib 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study To Collect Follow-up Clinical Data From Kidney Transplant Recipients Who Received Tofacitinib (CP-690,550) In Completed Phase 2 Studies
In Brief
An observational study evaluating Tofacitinib for Kidney Transplantation. Completed, enrolled 83 participants across 43 sites in 12 countries.
Detailed Summary
This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesAustralia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Spain, United States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartAug 2011
Primary CompletionJul 2012
TodayJul 2026
First PostedJun 17, 2011
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.0 years ago
Interventions
Tofacitinibdrug
Subjects who previously took 15 mg BID or 30 mg BID
Tofacitinibdrug
Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID